Kyowa Hakko Kirin Reports Significant Decrease in Off Time with Parkinson’s Disease Drug that is Currently Under Approval Review

Kyowa Hakko Kirin has released the results of a domestic PIII study on the novel Parkinson’s disease agent KW-6002 (istradefylline), for which an application is pending in Japan, demonstrating a statistically significant reduction in off-time in patients with Parkinson’s disease...read more